结直肠癌（CRC）是全球范围内发病率和死亡率较高的恶性肿瘤之一。HER2 基因扩增在 CRC 中的发生率仅为 3%～5%[1]，但与其预后密切相关，并已成为新的治疗靶点。随着新型 HER2 靶向治疗的出现，针对 HER2 ...

HER2 is one of 21 genes included in OncotypeDX ... says that for certain patients, the immunohistochemistry and FISH results never agree. “Just because you have a change in gene copy number ...

The analysis was performed on independent study sets of HER2-positive and negative/low breast cancers, already analyzed by central immunohistochemistry (IHC) and FISH testing. Phospho-HER2 and ...

The analysis was performed on independent study sets of HER2-positive and negative/low breast cancers, already analyzed by central immunohistochemistry (IHC) and FISH testing. Phospho-HER2 and ...

肝内胆管癌（intrahepatic cholangiocarcinoma, ICC）是一种高度异质性的肿瘤，分子分型是实施ICC 个体化治疗的基础。正确的检测方法对于全面筛选适用靶向药物的患者群体具有重要的临床意义。本共识基于国内外临床实践数据，结合国情，围绕ICC重要靶点进行制定，提出了15 条推荐意见，以期为ICC ...

HER2 classification relies on immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), which examines the number of copies of the HER2 gene inside a cancer cell. "On FISH ...

human epidermal growth factor receptor 2 (HER2)-negative (immunohistochemistry [IHC] 0, IHC 1+ or IHC 2+/in situ hybridization [ISH]-) breast cancer who have received prior endocrine-based therapy ...

HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. The approval by the US Food and ...

HER2 negative breast cancer (measured as HER2 score of IHC 0, IHC 1+ or IHC 2+/ISH-).2 Endocrine therapies are widely given consecutively in the early lines of treatment for HR positive metastatic ...